Amicus Therapeutics

News

BioMarin ends year with $4.8bn play for Amicus

BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.

News

CHMP backs Amicus' therapy for Pompe disease

Amicus Therapeutics could be just weeks away from getting EU approval for its new Pompe disease therapy Pombiliti after getting a positive opinion on the drug from the EMA's human medicines

News

Amicus' oral Fabry disease drug approved in US

Decision follows approval in Europe

News

Amicus to file Fabry drug after FDA changes mind

Regulator drops demand for further phase 3 trial.

News

Amicus set for share of Fabry market after NICE approval

England and Wales’ cost effectiveness watchdog NICE has given a final recommendation to a new treatment for the rare Fabry disease.

BioMarin ends year with $4.8bn play for Amicus

CHMP backs Amicus' therapy for Pompe disease

Amicus' oral Fabry disease drug approved in US

Amicus to file Fabry drug after FDA changes mind

Amicus set for share of Fabry market after NICE approval

Moderna jab on trial for cancer-causing syndrome

Discover a new era of healthcare panel engagement: Grounded ...

Amicus Therapeutics

Editor's Picks